Infertility Services Market in US 2017-2021 - Product Image

Infertility Services Market in US 2017-2021

  • ID: 4115321
  • Report
  • Region: United States
  • 80 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • AbbVie
  • CARE facility
  • Ferring Pharmaceuticals
  • Irvine Scientific
  • Monash IVF
  • Pantec Biosolutions
  • MORE
About Infertility Services

Infertility is the failure to achieve pregnancy after 12 months of unprotected intercourse. Infertility occurs due to the abnormal functioning of the female and male reproductive system. It can be treated with infertility drugs and through procedures such as artificial insemination, in-vitro fertilization, and surrogacy.

The analysts forecast the infertility services market in US to grow at a CAGR of 4.65% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the infertility services market in US for 2017-2021. To calculate the market size, the report considers the services carried out during treatment via infertility drugs and assisted reproductive technology (ART) services.

The report, Infertility Services Market in US 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- CARE facility
- CooperSurgical
- Ferring Pharmaceuticals
- Monash IVF
- Merck
- Vitrolife

Other prominent vendors
- AbbVie
- Apricus Biosciences
- AstraZeneca
- Auxogyn
- Eli Lilly
- EMD Serono
- IKS International
- InVitro Care
- INVO Bioscience
- Irvine Scientific
- LifeGlobal
- MedITEX
- NMC Health
- OB GYN Associates
- OvaScience
- Pantec Biosolutions
- Reproductive Medicine Associates of New Jersey
- The Sims Clinic
- TriHealth
- Virtus Health
- Xytex Cryo International

Market drivers
- Rising success rate of infertility treatments.
- For a full, detailed list, view the full report

Market challenges
- Limited reimbursements and lack of strict regulatory oversight.
- For a full, detailed list, view the full report

Market trends
- Upsurge in mergers and acquisitions.
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie
  • CARE facility
  • Ferring Pharmaceuticals
  • Irvine Scientific
  • Monash IVF
  • Pantec Biosolutions
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

Market overview

Vendor analysis

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 06: Market segmentation by underlying cause

PART 07: Market segmentation by services

Market overview

ART services market in US

Infertility drugs services market in US

PART 08: Market drivers

PART 09: Impact of drivers

PART 10: Market challenges

PART 11: Impact of drivers and challenges

PART 12: Market trends

PART 13: Vendor landscape

Competitive scenario

Other prominent vendors

PART 14: Key Vendor Analysis

CARE Fertility

CooperSurgical

Ferring Pharmaceuticals

Monash IVF

Merck

Vitrolife

PART 15: Appendix

List of abbreviations

PART 16: About the Author

List of Exhibits
Exhibit 01: US infertility services market segmentation: Overview
Exhibit 02: Product offerings
Exhibit 03: Assessment of regulatory bodies
Exhibit 04: Snapshot: Infertility services market in US
Exhibit 05: US fertility chart 2015
Exhibit 06: Stages of infertility treatment
Exhibit 07: Infertility services market in the US 2016-2021 ($ billions)
Exhibit 08: Side effects and success rates of infertility services in US
Exhibit 09: Impact of various factors on infertility services in US
Exhibit 10: Recommendations to vendors
Exhibit 11: Five forces analysis
Exhibit 12: Infertility services market in US by underlying cause
Exhibit 13: Diagnosis of infertility
Exhibit 14: Market segmentation by services 2016-2021(in %)
Exhibit 15: Snapshot: US fertility services market by product
Exhibit 16: Categories of ART services 2016
Exhibit 17: IVF overview
Exhibit 18: ART services market in US 2016-2021 ($ billions)
Exhibit 19: Comparison of fresh and frozen ART cycle
Exhibit 20: Infertility drugs services market in US 2016-2021($ billions)
Exhibit 21: Success rate of IVF procedures
Exhibit 22: ART procedures in US (in thousands)
Exhibit 23: Obesity prevalence in the US (2015)
Exhibit 24: Infertility rates by age
Exhibit 25: US birth rates by women
Exhibit 26: Impact of drivers
Exhibit 27: Cost breakdown of IVF by various stages in US
Exhibit 28: Impact of drivers and challenges
Exhibit 29: Notable M&A activity
Exhibit 30: Same sex married couples in US
Exhibit 31: CARE Fertility: Profile
Exhibit 32: CARE Fertility: Strength analysis
Exhibit 33: CARE Fertility: Strategy assessment
Exhibit 34: CARE Fertility: Opportunity assessment
Exhibit 35: CooperSurgical: Profile
Exhibit 36: CooperSurgical: Strength analysis
Exhibit 37: CooperSurgical: Growth strategy assessment
Exhibit 38: CooperSurgical: Opportunity assessment
Exhibit 39: Ferring Pharmaceuticals: Profile
Exhibit 40: Ferring Pharmaceuticals: Strength analysis
Exhibit 41: Ferring Pharmaceuticals: Strategy assessment
Exhibit 42: Ferring Pharmaceuticals: Opportunity assessment
Exhibit 43: Monash IVF: Profile
Exhibit 44: Monash IVF: Strength analysis
Exhibit 45: Monash IVF: Strategy assessment
Exhibit 46: Monash IVF: Opportunity assessment
Exhibit 47: Merck: Profile
Exhibit 48: Merck: Strength analysis
Exhibit 49: Merck: Strategy assessment
Exhibit 50: Merck: Opportunity assessment
Exhibit 51: Vitrolife: Profile
Exhibit 52: Vitrolife: Strength analysis
Exhibit 53: Vitrolife: Strategy assessment
Exhibit 54: Vitrolife: Opportunity assessment
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • AbbVie
  • CARE facility
  • Ferring Pharmaceuticals
  • Irvine Scientific
  • Monash IVF
  • Pantec Biosolutions
  • MORE
New Report Released: – Infertility Services Market in US 2017-2021

The author of the report recognizes the following companies as the key players in the infertility services market in US: CARE facility, CooperSurgical, Ferring Pharmaceuticals, Monash IVF, Merck, and Vitrolife.

Other Prominent Vendors in the market are: AbbVie, Apricus Biosciences, AstraZeneca, Auxogyn, Eli Lilly, EMD Serono, IKS International, InVitro Care, INVO Bioscience, Irvine Scientific, LifeGlobal, MedITEX, NMC Health, OB GYN Associates, OvaScience, Pantec Biosolutions, Reproductive Medicine Associates of New Jersey, The Sims Clinic, TriHealth, Virtus Health, and Xytex Cryo International.

Commenting on the report, an analyst from the research team said: “One trend in market is rise in same sex marriages. Social and legal acceptance of same sex marriages has also led to a rise in sperm donations and the use of fertility services. In the US, it is estimated that same sex couples are parents to around six million children. The use of donor sperm by same sex female couples increased from 15% before the legalization of same sex marriages to 20% after the legalization of the same. The invalidation of the Defense of Marriage Act in 2013 has led to an increase in demand for fertility services in the US.”

According to the report, one driver in market is rising success rate of infertility treatments. Most fertility services and infertility drugs, increase the success rates of live births. Success rates have improved dramatically over the past 10 years. Infertility treatments increase pregnancy rates from about 3% to about 12% for people under the age 40, and to 7% in those above the age 40. According to the CDC, in 2014, IVF had a 40% success rate compared with other ART, such as ZIFT, GIFT, and ICSI, which had success rates of 33%, in people aged below 35 years. The pregnancy rate of women undergoing IVF is about 40% in women under the age of 40. Success rates from frozen embryo transfers are also increasing, as are the number of fertility cycles. These services benefit women whose infertility is due to issues with ovulation. These services can help in correcting physiological complications that prevent the eggs from joining and creating embryo that implants on the female's uterine wall.

Further, the report states that one challenge in market is limited reimbursements and lack of strict regulatory oversight. Infertility treatment is considered a lifestyle procedure rather than serious medicine. Health insurance plans commonly, but not always, pay for services related to testing for infertility. In the US, which does not have any infertility coverage mandate, most insurance policies do not help with fertility and IVF service payment. Some insurance covers testing and treatment, up to and including IUI but does not cover IVF. In addition, at times, the monitoring of IVF ovarian stimulation (blood and ultrasound tests) is covered but IVF codes are not covered.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • CARE facility
  • CooperSurgical
  • Ferring Pharmaceuticals
  • Monash IVF
  • Merck
  • Vitrolife
  • AbbVie
  • Apricus Biosciences
  • AstraZeneca
  • Auxogyn
  • Eli Lilly
  • EMD Serono
  • IKS International
  • InVitro Care
  • INVO Bioscience
  • Irvine Scientific
  • LifeGlobal
  • MedITEX
  • NMC Health
  • OB GYN Associates
  • OvaScience
  • Pantec Biosolutions
  • Reproductive Medicine Associates of New Jersey
  • The Sims Clinic
  • TriHealth
  • Virtus Health
  • Xytex Cryo International
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll